Companies › The Skin Center Dermatology Group
1 active drug program in 3 registered trials: 1 Phase 4, 1 Phase 2, 1 Phase 1; Infectious disease, Oncology; next expected readout Dec 2026.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| Tirbanibulin Tyrosine-protein kinase SRC inhibitor | SRC | Phase 4 | Warts Hand; Cell Carcinoma; Keratinocyte Carcinoma | Dec 2026 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT06791525 | Tirbanibulin | Phase 4 | Warts Hand | Infectious disease | Dec 2026 |
| NCT06112522 | Tirbanibulin | Phase 2 | Cell Carcinoma | Oncology | Dec 2027 |
| NCT07010692 | Tirbanibulin | Phase 1 | Keratinocyte Carcinoma | Oncology | May 2030 |
Cantex Pharmaceuticals Tetraphase Pharmaceuticals Amivas Shanghai Jiatan Pharmatech Laboratorio Farmaceutico SIT srl
Pipelines of the same shape: areas, drug types, target families, stage and cash runway.
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.